Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life sciences, has announced the appointment of Dr Kemal Malik as ...

Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life sciences, notes today that its portfolio company, Achilles Therapeutics has ...

Syncona Limited (LON:SYNC), a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, today announced a $51.0 million new commitment in a ...

Syncona Ltd (LON: SYNC), a leading healthcare company focused on founding, building and funding global leaders in life science, has noted that its portfolio company, Autolus Therapeutics plc today announced ...

Syncona Ltd (LON: SYNC), a leading healthcare company focused on founding, building and funding global leaders in life science, today announced that it has made a $80.0 million commitment in ...

Syncona Ltd (LON: SYNC) has today announced a new portfolio company, Azeria Therapeutics in a £32 million Series B financing in which Syncona has committed £29.5 million alongside existing investor ...

Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding global leaders in life sciences, today announced that it has committed £48.0 million of a £50.4 million ...

Syncona Ltd (LON:SYNC), a leading healthcare company focused on founding, building and funding global leaders in life science, today issued its quarterly update covering the period from 1 April to ...

Syncona Limited (LON:SYNC), a leading healthcare company focused on founding, building and funding global leaders in life science, announced that Melanie Gee has been appointed to the Group’s Board of ...

Syncona Ltd (LON:SYNC) announced the foundation of Quell Therapeutics (Quell), a new cell therapy company, with a £35 million commitment in a Series A financing of which Syncona has committed ...